WilmerHale Advises PTC Therapeutics on up to $300 Million Royalty Sale

WilmerHale Advises PTC Therapeutics on up to $300 Million Royalty Sale

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

WilmerHale advised PTC Therapeutics, Inc. (NASDAQ: PTCT), a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines for patients with rare diseases, on the recent sale to Royalty Pharma plc (NASDAQ: RPRX) of its remaining royalty interest in Evrysdi®. PTC received an upfront payment of $240 million and may receive up to $60 million in sales-based milestone payments in the future. The agreement builds on the strategic partnership established in 2020 with Royalty Pharma.

The WilmerHale team advising PTC Therapeutics was led by George W. Shuster, Jr. and Nathan Moore and included Brian Johnson, Jeffries Oliver-Li, and Tim Kolankowski.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel